European project concerning the guidelines on medicinal products derived from human blood and plasma.
The Biotechnology/Pharmacy Working Party (BPWP) decided in October 1989 to put on its working programme the elaboration of a guideline on medicinal products derived from human blood and plasma. This has been determined by the adoption of Directive 89/381/EEC extending the scope of the EEC pharmaceutical legislation to medicinal products derived from human plasma. Because Directive 89/381/EEC will come into force on 1 Jan. 1992, the existing products derived from plasma should be reviewed in order to harmonize them with the EEC requirements before 1 Jan. 1993. In this paper, I give an account of the main points and questions addressed by the BPWP draft in order to stimulate comments from producers and regulatory agencies.
Horaud
F
F
Institut Pasteur, Paris.
D001688:Biological Products / Q000302:isolation & purification / Q000592:standards*; D001769:Blood / Q000382:microbiology*; D004340:Drug Contamination / Q000517:prevention & control; D005060:Europe; D006801:Humans; D010949:Plasma / Q000382:microbiology; D014780:Viruses / Q000302:isolation & purification
D001688:Biological Products